New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:32 EDTADXSAdvaxis announces first patient dosed in Phase 1/2 ADXS-HPV
Advaxis announced that the first patient has been dosed in a Phase 1/2 “window of opportunity” study. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the “window” of time between initial diagnosis and minimally invasive transoral robotic surgery to remove their tumors. This investigator-initiated clinical study is designed to enroll 25 patients with human papillomavirus-positive stage II-IV squamous cell carcinoma of the oropharynx who are scheduled to undergo TORS. The primary objective of this study is to assess the safety, efficacy, and immunogenicity of ADXS-HPV in this patient population prior to undergoing surgery.
News For ADXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:38 EDTADXSAdvaxis to receive $1.7M through NJ NOL program
Advaxis announced it has received preliminary approval for a $1.9M tax credit from the New Jersey Technology Business Tax Certificate Transfer, or NOL, Program for the year 2014. The company anticipates that it will be able to transfer this credit and receive approximately $1.7M in cash in mid-December.
November 12, 2014
07:35 EDTADXSAdvaxis submits IND application for ADXS-HPV Phase 1/2 study, MEDI4736
Advaxis (ADXS) announced that the company has submitted an Investigational New Drug application, or IND, to the FDA to conduct a Phase 1/2 study of ADXS-HPV alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. This follows the press release issued in July announcing the clinical trial collaboration between Advaxis and MedImmune, the global biologics research and development arm of AstraZeneca (AZN).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use